Healthcare Industry News: Bard
News Release - September 15, 2008
Tryton Medical Announces Two Key Hires and Relocation to Research Triangle Park, N.C.Company Poised for European Launch of Lead Product, Implementation of U.S. Clinical Strategy
RESEARCH TRIANGLE PARK, N.C.--(HSMN NewsFeed)--Tryton Medical, Inc., a developer of novel stent systems for the treatment of cardiovascular disease, announced today that the company has appointed Brett Farabaugh to the position of chief financial officer and Douglas Ferguson as vice president, Regulatory & Clinical.
“With the addition of Brett and Douglas, our management team now holds more than 60 years of collective experience leading companies in the medical technology arena,” said J. Greg Davis, president and CEO of Tryton Medical. “This leadership experience, combined with that of the members of our board of directors, help solidify Tryton as the leader in the bifurcation space and will be instrumental as we look toward commercialization of our unique stent system in Europe this fall and continued planning for our U.S. clinical trial. We are excited about the benefits that our technology promises for patients with cardiovascular disease.”
Tryton’s novel Side Branch Stent System™, which is designed to offer a dedicated strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation, received CE Mark approval earlier this year. The company will launch the product in Europe in the coming weeks.
Brett Farabaugh brings to Tryton extensive finance experience from entrepreneurial companies both public and private. Most recently Farabaugh held the position of chief financial officer for StrikeIron, Inc., a venture-backed web-based data delivery company. Prior to StrikeIron, Farabaugh served as chief financial officer of Icoria, Inc. (formerly Paradigm Genetics, Inc.), a publicly traded biotech company acquired by Clinical Data, Inc. in 2005. He has also held finance and executive roles at Nuada Pharmaceuticals, Inc. and PricewaterhouseCoopers.
Douglas Ferguson has more than 18 years of experience in regulatory and clinical affairs for medical device companies including roles in compliance, R&D, and quality assurance. In positions at Becton Dickinson and Company, Boston Scientific Corporation, and C.R. Bard, Inc., Ferguson’s leadership was instrumental in helping to bring a variety of products from early development to commercialization.
Company Relocates to Research Triangle Park, N.C.
Tryton also announced today that the company has relocated from Newton, Mass. to Research Triangle Park, N.C.
“Research Triangle Park’s prominence as a global center for technology research and development makes it an ideal location for our growing company,” said Mr. Davis. “Durham, known as ‘the city of Medicine,’ also has a reputation as a top center for entrepreneurial companies. We are pleased that it will serve as Tryton’s global headquarters.”
About the Tryton Side-Branch Stent System
The Side Branch Stent System is designed to offer a dedicated strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. These areas of the vascular system are a common location for plaque and are particularly challenging to treat with currently available stent systems. Approximately twenty percent of patients treated for coronary artery disease are treated for bifurcated lesions.
Tryton’s highly deliverable cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug eluting stent is then placed in the main vessel.
The Tryton Side Branch Stent System demonstrated excellent six-month clinical results in a first-in-man study of the system in 30 patients, with no restenosis occurring in the side-branch artery. The stent system is an investigational device in the U.S. and has received CE Mark approval in Europe.
About Tryton Medical, Inc.
Tryton Medical, Inc., located in Research Triangle Park, N.C., is a leading developer of novel stent systems for the treatment of bifurcation lesions. The company’s Side Branch Stent System is designed to offer a dedicated strategy for treating these challenging cases, which occur in approximately twenty percent of patients treated for coronary artery disease. The privately held company is backed by Spray Ventures, PTV Sciences, RiverVest Ventures. For more information please visit www.trytonmedical.com.
Source: Tryton Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.